PHOENIX is a Phase 2 study planning to enroll 25 patients in each of the following diagnosis groups:
- CKD associated with type 1 diabetes (T1D)
- IgA nephropathy (IgAN)
- Focal segmental glomerulosclerosis (FSGS)
- Autosomal dominant polycystic kidney disease (ADPKD)
PHOENIX will enroll approximately 100 patients in total, and all patients who enroll in PHOENIX will receive bardoxolone methyl. No patients will receive placebo (an inactive “sugar pill” sometimes used in clinical trials).
Participation in PHOENIX may last up to 16 weeks, and will include 10 study visits and 6 scheduled phone calls.
The investigational drug, study-related procedures, and doctor visits will be provided at no cost. If you travel to the site for your study visits, travel expenses will be reimbursed, and compensation for study-related time may be provided.
The design of this study is intended to provide data that will answer important questions researchers are asking about how bardoxolone methyl may affect kidney function in patients with different types of kidney disease. As a Phase 2 study, Reata will closely evaluate the data generated from PHOENIX to determine how to best continue studying potential effects of bardoxolone methyl on kidney function.